Genmab AS (OCSE:GMAB) Additional Paid-In Capital : kr13,536 Mil(As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Genmab AS Additional Paid-In Capital?

Genmab AS's quarterly additional paid-in capital declined from Sep. 2024 (kr12,657 Mil) to Dec. 2024 (kr12,510 Mil) but then increased from Dec. 2024 (kr12,510 Mil) to Mar. 2025 (kr13,536 Mil).

Genmab AS's annual additional paid-in capital increased from Dec. 2022 (kr12,442 Mil) to Dec. 2023 (kr12,645 Mil) but then declined from Dec. 2023 (kr12,645 Mil) to Dec. 2024 (kr12,510 Mil).

Genmab AS Additional Paid-In Capital Historical Data

The historical data trend for Genmab AS's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Additional Paid-In Capital Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

12,022.25

12,051.43

12,441.87

12,645.13

12,510.08

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															12,423.65	12,477.51	12,657.44	12,510.08	13,536.43

Genmab AS Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Genmab AS Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Genmab AS's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.